NOVONESIS (NOVOZYMES)-ADR Business Summary

Novonesis (ticker: NVZMY) is a global leader in the biosolutions market, established through the 2024 merger of industrial enzyme pioneer Novozymes and microbial specialist Chr. Hansen. The company generates revenue primarily through the sale of biological inputs, including enzymes, microbial cultures, and probiotics, supplemented by technical support services that integrate these solutions into complex industrial processes. Operations are structured into two core segments: Planetary Health Biosolutions, which accounts for approximately 56% of sales across household care, bioenergy, and agriculture, and Food & Health Biosolutions, representing 44% of revenue from human health, dairy, and beverage applications. Holding a dominant market share of nearly 50% in industrial enzymes, Novonesis competes directly with specialty ingredient giants such as International Flavors & Fragrances (IFF), dsm-firmenich, and Kerry Group, distinguishing itself through a high-density R&D pipeline focused on sustainable, bio-based alternatives to traditional chemical processing. The executive leadership team is led by President and CEO Ester Baiget, a chemical engineer with over 25 years of global experience who previously served as President of Dow Industrial Solutions. Key C-suite members include Executive Vice President and CFO Rainer Lehmann, formerly of Sartorius, Chief Scientific Officer Claus Crone Fuglsang, and Chief Operating Officer Anders Lund. The Board of Directors is chaired by Cees de Jong, the former CEO of Chr. Hansen, with Heine Dalsgaard serving as Vice Chair. Novonesis is anchored by its majority shareholder, Novo Holdings A/S—the investment arm of the Novo Nordisk Foundation—which provides long-term capital stability and is represented on the board by CEO Kasim Kutay. This governance structure supports the ongoing integration of the company's legacy platforms, combining Novozymes' 2000 spin-off heritage from Novo Nordisk with Chr. Hansen’s deep microbial expertise dating back to 1874.